Academic
Publications
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients,10.1

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients   (Citations: 10)
BibTex | RIS | RefWorks Download
Francesca Gay, Suzanne R. Hayman, Martha Q. Lacy, Francis Buadi, Morie A. Gertz, Shaji Kumar, Angela Dispenzieri, Joseph R. Mikhael, P. Leif Bergsagel, David Dingli, Craig B. Reeder, John A. Lusthttp://academic.research.microsoft.com/io.ashx?type=5&id=14056097&selfId1=0&selfId2=0&maxNumber=12&query=
The objective of this case-control study was to compare the efficacy and toxicity of lenalidomide plus dexamethasone (len/ dex) versus thalidomide plus dexametha- sone (thal/dex) as initial therapy for newly diagnosed myeloma. We retrospectively studied 411 newly diagnosed patients treated with len/dex (228) or thal/dex (183) at the Mayo Clinic. The differences were similar in a matched-pair analysis that adjusted for age, sex, transplantation sta- tus, and dexamethasone dose. The pro- portions of patients achieving at least a partial response to len/dex and thal/dex were 80.3% versus 61.2%, respectively (P < .001); very good partial response rates were 34.2% and 12.0%, respectively (P < .001). Patients receiving len/dex had longer time to progression (median, 27.4 vs 17.2 months; P.019), progression- free survival (median, 26.7 vs 17.1 months; P.036), and overall survival (median not reached vs 57.2 months; P.018). A similar proportion of patients in the 2 groups experienced at least one grade 3 or 4 adverse event (57.5% vs 54.6%, P.568). Main grade 3 or 4 toxicities of len/dex were hematologic, mainly neutro- penia (14.6% vs 0.6%, P < .001); the most common toxicities in thal/dex were ve- nous thromboembolism (15.3% vs 9.2%, P.058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex ap- pears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results. (Blood. 2010;115:1343-1350)
Journal: Blood , vol. 115, no. 7, pp. 1343-1350, 2010
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Sort by: